Tirzepatide is a dual GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound for specific FDA-approved indications. Randomized trials support diabetes and chronic weight-management uses. Public discussion should remain separate from label language and trial populations.
Dual GIP/GLP-1 receptor agonist
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound for specific FDA-approved indications. Randomized trials support diabetes and chronic weight-management uses. Public discussion should remain separate from label language and trial populations.
Evidence review
Last reviewed Jul 1, 2026
Next review Jul 29, 2026
Evidence snapshot
FDA-approved as Mounjaro for Type 2 diabetes (May 2022) and Zepbound for chronic weight management (November 2023).
SURMOUNT-1 Phase 3 trial showed mean weight loss of 22.5% at 72 weeks at the highest dose, published in NEJM (2022).
SURPASS-2 trial demonstrated superior A1C reduction versus semaglutide in Type 2 diabetes patients.
Large media and community attention is a public-interest signal, not evidence of additional approved indications.
Ongoing trials are evaluating cardiovascular outcomes, sleep apnea, and liver disease (MASH) indications.
Research record
What the evidence record says
- Evidence grade
- Not Graded
- Regulatory status
- Tirzepatide regulatory status has not been fully reviewed by Peptide Report editorial team. See company profiles and regulatory watch for current status.
Evidence records
Studies, registries, reviews, and regulatory records
Evidence review pending
- Detailed evidence review for Tirzepatide is pending editorial assessment. Current summary reflects available public records.
Records: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2), SURMOUNT-1: Tirzepatide for Obesity: ClinicalTrials.gov
Evidence timeline
What changed, and when
Peptide Report last reviewed Tirzepatide on 2026-07-01.
Records: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Direct answers
Frequently asked questions
What is Tirzepatide?
Tirzepatide is a dual gip/glp-1 receptor agonist tracked by Peptide Report. See the full profile for current editorial assessment.
Open research questions
What is still unknown
- What is the complete human evidence base for Tirzepatide?
- What are the long-term safety considerations for Tirzepatide?
Tracked claims
Tirzepatide showed weight loss exceeding 20% in the SURMOUNT-1 Phase 3 clinical trial.
Evidence level: Peer reviewed
Sources: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), SURMOUNT-1: Tirzepatide for Obesity: ClinicalTrials.gov
How to read this: Cite the NEJM SURMOUNT-1 publication directly. Results are specific to the trial population and dosing protocol.
Tirzepatide is FDA-approved for Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
Evidence level: Primary regulatory
Sources: FDA Approves Mounjaro (Tirzepatide) for Type 2 Diabetes, FDA approves Zepbound (tirzepatide) for obesity (2023)
How to read this: Confirm approval status against FDA records on each review cycle. Track any label changes or new indications.
Tirzepatide demonstrated superior glucose control versus semaglutide in head-to-head trials.
Evidence level: Peer reviewed
Sources: Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)
How to read this: SURPASS-2 compared tirzepatide to semaglutide in Type 2 diabetes. Do not generalize to weight loss comparisons.
Online discussions frame tirzepatide as the most effective weight loss drug available.
Evidence level: Community discussion
Sources: Mounjaro (tirzepatide): The newest diabetes and obesity medication, The Best MOUNJARO Alternative (Without the Side Effects) - Dr. Berg
How to read this: Track as media claims that may exceed clinical evidence. Separate approved indications from community hype.
Linked public records
Regulatory actions involving Tirzepatide
Ready Med: FDA Warning Letter 730317
Agency warning · Open public record
FDA stated that Ready Med's website claims about compounded semaglutide and tirzepatide could imply equivalence with approved drugs and could obscure which entity compounded the products.
Compounds: Semaglutide, Tirzepatide
D&H Medical Services: FDA Warning Letter 728238
Agency warning · Open public record
FDA issued a warning letter concerning website presentation and marketing claims for compounded semaglutide and tirzepatide products. The linked source is the agency's complete public record.
Compounds: Semaglutide, Tirzepatide
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List
Proposal · Proposal; comment period closed
FDA proposed excluding three GLP-1 active ingredients from the 503B Bulks List after preliminarily finding no clinical need for outsourcing facilities to compound them from bulk substances. The proposal is not a final determination.
Compounds: Semaglutide, Tirzepatide
Gram Peptides: FDA Warning Letter 721806
Agency warning · Open public record
The FDA said Gram Peptides marketed unapproved new drugs for human use despite research-only labeling. Warning letter 721806 details the finding.
Companies: Gram Peptides
Compounds: Retatrutide, Tirzepatide
FDA announces warning letters to 30 telehealth companies over compounded GLP-1 marketing
Agency warnings · Agency initiative announced
FDA announced 30 warning letters addressing claims that could imply compounded GLP-1 products were the same as FDA-approved products or obscure the source of the compounded product.
Compounds: Semaglutide, Tirzepatide
FDA announces intent to act against mass-marketed non-approved compounded GLP-1 drugs
Intent announced · Policy statement
FDA announced intended enforcement steps involving GLP-1 active pharmaceutical ingredients used in mass-marketed non-approved compounded drugs and misleading direct-to-consumer promotion. The statement named Hims & Hers among the companies in scope but was not itself a final adjudication against that company.
Companies: Hims & Hers
Compounds: Semaglutide, Tirzepatide
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate Tirzepatide claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Formspree processes this submission for Peptide Report. Privacy notice.
Sources on this page
Each source record is linked to the claim or evidence note it supports.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Phase 3 trial of tirzepatide for obesity showing mean weight loss of 22.5% at 72 weeks at the highest dose.
8 linked pagesOpen original ·
nejm-tirzepatide-surmount1-2022Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)
Head-to-head trial showing tirzepatide superior to semaglutide for A1C reduction in Type 2 diabetes.
3 linked pagesOpen original ·
nejm-tirzepatide-surpass2-2021SURMOUNT-1: Tirzepatide for Obesity: ClinicalTrials.gov
ClinicalTrials.gov registry for the SURMOUNT-1 Phase 3 trial of tirzepatide for obesity, sponsored by Eli Lilly.
5 linked pagesOpen original ·
clinicaltrials-gov-surmount1SURMOUNT-4: Extended Treatment with Tirzepatide: ClinicalTrials.gov
ClinicalTrials.gov registry for SURMOUNT-4, evaluating tirzepatide for extended obesity treatment.
3 linked pagesOpen original ·
clinicaltrials-gov-surmount4FDA Approves Mounjaro (Tirzepatide) for Type 2 Diabetes
FDA approval of Mounjaro (tirzepatide) injection for Type 2 diabetes, NDA 215866.
10 linked pagesOpen original ·
fda-mounjaro-approval-2022FDA Approves Zepbound (Tirzepatide) for Chronic Weight Management
FDA approved Zepbound (tirzepatide) in November 2023 for chronic weight management in adults with obesity, used with diet and exercise. NDA 217806.
11 linked pagesOpen original ·
fda-zepbound-approval-2023Mounjaro (tirzepatide): The newest diabetes and obesity medication
Medical doctor explainer video on Mounjaro/tirzepatide with significant views. Tracked as media signal for public claim patterns.
2 linked pagesOpen original ·
youtube-mcgowan-mounjaro-2023The Best MOUNJARO Alternative (Without the Side Effects) - Dr. Berg
High-view video discussing Mounjaro alternatives. Tracked as media signal for alternative-seeking behavior.
2 linked pagesOpen original ·
youtube-berg-mounjaro-alternative-2023How Do Ozempic, Mounjaro & Other GLP-1 Agonists Work? | Dr. Zachary Knight & Dr. Andrew Huberman
Huberman Lab discussion on GLP-1 mechanism. Tracked as expert media signal for public understanding.
5 linked pagesOpen original ·
youtube-huberman-glp1-2025Related compounds
Retatrutide
Retatrutide has produced large weight reductions in randomized Phase 2 and Phase 3 trials, but it remains unapproved. Lo...
Regulatory watchSemaglutide
Semaglutide is a GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus for specific FDA-approved indications. Ran...
Evidence reviewStay informed
Track Tirzepatide with Peptide Report
Get FDA Watch Alerts for Tirzepatide
Subscribe for regulatory updates, new trial data, and source-backed claim revisions.
See claims about Tirzepatide fact-checked
2 video claims checked in our video claim scanner.
Compare Tirzepatide with similar compounds
3 comparison pages available:
Retatrutide vs Tirzepatide · Semaglutide vs Tirzepatide for Weight Loss · Tirzepatide vs Semaglutide